Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter

Journal of Managed Care Pharmacy

Volumn 14, Issue 9, 2008, Pages 858-869

  Nordstrom, Beth L ^a   Luo, Weixiu ^a   Fraeman, Kathy H ^a   Whyte, Joanna L ^b   Nordyke, Robert J ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Amgen   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; IRINOTECAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; UNINDEXED DRUG;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; ONCOLOGY; OUTPATIENT CARE; PREDICTION; PREVALENCE; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; UNITED STATES;

EID: 57749110462     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.9.858     Document Type: Article

References (16)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616-34.
2. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214-21.
3. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25(3 Suppl 7):43-46.
4. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol. 2000;37(4 Suppl 6):14-17.
5. Aranesp (darbepoetin alfa) for injection. Product monograph. Thousand Oaks, CA: Amgen, Inc.; 2004.
6. Procrit (epoetin alfa) for injection. Product monograph. Thousand Oaks, CA: Amgen, Inc.; 2005.
7. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708-14.
8. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(9392):1255-60.
9. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960-72.
10. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26(7):1040-50.
11. U.S. Food and Drug Administration. Complete response and safety labeling change order. July 30, 2008. Available at: www.fda.gov/cder/drug/ infopage/RHE/aranesp/signed.pdf. Accessed October 7, 2008.
12. Aranesp (darbepoetin alfa) for injection. Product monograph. Thousand Oaks, CA: Amgen, Inc.; 2008.
13. Procrit (epoetin alfa) for injection. Product monograph. Thousand Oaks, CA: Amgen, Inc.; 2008.
14. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132-49. Available at: www.jco.ascopubs.org/cgi/reprint/26/1/132. Accessed October 7, 2008.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, V.2.2009: Cancer- and chemotherapy-induced anemia. Available at: www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed September 15, 2008.
16. Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. (Based on November 2007 SEER data submission.) Available at: www.seer.cancer.gov/ csr/1975_2005/ (Accessed October 8, 2008.